Home
VERA
VERA News

Latest Vera Therapeutics Inc. (VERA) News on February 22, 2025

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

9 days ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

18 days ago

Wolfe Research Initiates Coverage on Vera Therapeutics With Outperform Rating, $49 Price Target

MT Newswires

25 days ago

Goldman Sachs Initiates Vera Therapeutics at Buy With $58 Price Target

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a month ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

a month ago

Vera Therapeutics Acquires Global Rights to Dual BAFF/APRIL Inhibitor

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

GlobeNewswire

a month ago

Vera Therapeutics Acquires Global Rights to Novel, Next Generation Dual BAFF/APRIL Inhibitor

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

GlobeNewswire

a month ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

MT Newswires

2 months ago

Vera Therapeutics Insider Sold Shares Worth $753,680, According to a Recent SEC Filing

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

2 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

GlobeNewswire

3 months ago

Vera Therapeutics Appoints Jason S. Carter as Chief Legal Officer

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

3 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

Zacks

3 months ago

Wall Street Analysts Think Vera Therapeutics (VERA) Could Surge 27.26%: Read This Before Placing a Bet

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

GlobeNewswire

3 months ago

Vera Therapeutics Partners with University of Michigan on the NEPTUNE Match Project and PIONEER Study

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

3 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Vera Therapeutics to Participate at Upcoming Investor Conferences

GlobeNewswire

3 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

MT Newswires

3 months ago

Wedbush Raises Vera Therapeutics' Price Target to $38 From $30, Maintains Neutral rating

MT Newswires

3 months ago

Vera Therapeutics Shares Rise After Q3 Results

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

GlobeNewswire

3 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

GlobeNewswire

4 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

TipRanks

4 months ago

Vera Therapeutics price target raised to $64 from $56 at Guggenheim

Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Investor's Business Daily

4 months ago

Vera Therapeutics Breaks Out On Promising Results For Kidney Drug

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

GlobeNewswire

4 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

MT Newswires

4 months ago

Vera Therapeutics Shares Jump After Supportive Data From Phase 2b Trial of Kidney Disease Drug Candidate

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Benzinga

4 months ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug

Investor's Business Daily

4 months ago

Vera Therapeutics Eyes Breakout On Promising Results For Kidney Drug

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

GlobeNewswire

4 months ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

MT Newswires

4 months ago

Scotiabank Initiates Vera Therapeutics at Sector Outperform

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

5 months ago

Vera Therapeutics Expands Development of Kidney Disease Drug Pipeline

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

GlobeNewswire

5 months ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

GlobeNewswire

5 months ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

Insider Monkey

5 months ago

Is Vera Therapeutics Inc. (VERA) the Best Performing Small-Cap Stock in 2024?

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

GlobeNewswire

5 months ago

Vera Therapeutics to Host In-Person R&D Day in New York to Discuss Potential Indication Expansion for Atacicept on October 2, 2024

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

GlobeNewswire

5 months ago

Vera Therapeutics Completes Enrollment for Primary Endpoint in Pivotal Phase 3 ORIGIN 3 Trial of Atacicept in IgAN

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Insider Monkey

6 months ago

Vera Therapeutics, Inc. (VERA): Among the Best Mid-Cap Healthcare Stocks To Buy Now

Adobe and 2 More Stocks Added to JP Morgan Focus List. Here’s Why.

Barrons.com

6 months ago

Adobe and 2 More Stocks Added to JP Morgan Focus List. Here’s Why.

Adobe Stock Added to JP Morgan Focus List. Here’s Why.

Barrons.com

6 months ago

Adobe Stock Added to JP Morgan Focus List. Here’s Why.

Vera Therapeutics to Participate at September Investor Conferences

GlobeNewswire

6 months ago

Vera Therapeutics to Participate at September Investor Conferences

Vera Therapeutics, Inc.'s (NASDAQ:VERA) Intrinsic Value Is Potentially 88% Above Its Share Price

Simply Wall St.

6 months ago

Vera Therapeutics, Inc.'s (NASDAQ:VERA) Intrinsic Value Is Potentially 88% Above Its Share Price

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

6 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

6 months ago

Wedbush Cuts Vera Therapeutics' Price Target to $30 From $32, Maintains Neutral rating

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

GlobeNewswire

6 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

8 months ago

Vera Therapeutics Appoints David Johnson as Chief Operating Officer

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

GlobeNewswire

8 months ago

Vera Therapeutics Announces Appointment of Industry Veteran David L. Johnson as Chief Operating Officer

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

GlobeNewswire

8 months ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire

8 months ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

8 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

9 months ago

Vera Therapeutics Gets FDA Breakthrough Therapy Designation for Immunoglobulin A Nephropathy Treatment

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

GlobeNewswire

9 months ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

GlobeNewswire

9 months ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

MT Newswires

9 months ago

Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing

MT Newswires

9 months ago

Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

GlobeNewswire

9 months ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

10 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week

Simply Wall St.

10 months ago

Vera Therapeutics, Inc.'s (NASDAQ:VERA) high institutional ownership speaks for itself as stock continues to impress, up 5.0% over last week

Health Care Roundup: Market Talk

The Wall Street Journal

10 months ago

Health Care Roundup: Market Talk

Could This Stock Be the Next Biotech Buyout?

Motley Fool

10 months ago

Could This Stock Be the Next Biotech Buyout?

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

GuruFocus.com

10 months ago

Insider Sells at Vera Therapeutics Inc: SVP, Finance, Chief Accounting Officer Joseph Young ...

Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

Yahoo Finance Video

10 months ago

Vertex Pharmaceuticals to buy Alpine Immune Sciences in $4.9B deal

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Barrons.com

a year ago

ARS Pharmaceuticals, Nuvalent, and More Stocks See Action From Activist Investors

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

GlobeNewswire

a year ago

Vera Therapeutics Announces Two Oral Presentations at the 61st European Renal Association Congress

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

a year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

GlobeNewswire

a year ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Simply Wall St.

a year ago

Estimating The Fair Value Of Vera Therapeutics, Inc. (NASDAQ:VERA)

Wall Street Analysts Think Dave & Buster's (PLAY) Is a Good Investment: Is It?

Zacks

a year ago

Wall Street Analysts Think Dave & Buster's (PLAY) Is a Good Investment: Is It?

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

GlobeNewswire

a year ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Leslie’s, Inc. Announces First Quarter Fiscal 2024 Financial Results

GlobeNewswire

a year ago

Leslie’s, Inc. Announces First Quarter Fiscal 2024 Financial Results

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

GlobeNewswire

a year ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Factors Setting the Tone for Vista Outdoor (VSTO) Q3 Earnings

Zacks

a year ago

Factors Setting the Tone for Vista Outdoor (VSTO) Q3 Earnings

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

GlobeNewswire

a year ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Why Is Fiverr (FVRR) Stock Rocketing Higher Today

StockStory

a year ago

Why Is Fiverr (FVRR) Stock Rocketing Higher Today

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

ACCESSWIRE

a year ago

Protagonist Therapeutics to Participate in Fireside Chat at Guggenheim Healthcare Talks 2024

Bank of America: Buy, Sell, or Hold?

Motley Fool

a year ago

Bank of America: Buy, Sell, or Hold?

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

GlobeNewswire

a year ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

3 Great Dividend Stocks to Spice Up Your Portfolio

Motley Fool

a year ago

3 Great Dividend Stocks to Spice Up Your Portfolio

Atlantic Union Bankshares Corporation Declares Quarterly Common Stock Dividend and Preferred Stock Dividend

Business Wire

a year ago

Atlantic Union Bankshares Corporation Declares Quarterly Common Stock Dividend and Preferred Stock Dividend

Reuters

a year ago

TABLE-LNG tankers heading to Britain, Belgium, the Netherlands and Germany

Reuters

a year ago

UPDATE 4-Texas Freeport LNG unit faces month-long outage after winter storm

Reuters

a year ago

UPDATE 3-Biden pauses LNG export approvals after pressure from climate activists

BP Eyes FID for Trinidad's Calypso Deepwater Gas Field by 2025

Zacks

a year ago

BP Eyes FID for Trinidad's Calypso Deepwater Gas Field by 2025

Business Wire

a year ago

AMTD Digital’s Entertainment and Movie Businesses Are Estimated to Contribute Significantly to Net Profit

Reuters

a year ago

GLOBAL LNG-Asia spot prices remain flat below $10/mmBtu despite geopolitical risks

Biogas Traders Become Hot Commodities on Demand for Clean Fuel

Bloomberg

a year ago

Biogas Traders Become Hot Commodities on Demand for Clean Fuel

Q3 Earnings Roundup: Boston Beer (NYSE:SAM) And The Rest Of The Beverages and Alcohol Segment

StockStory

a year ago

Q3 Earnings Roundup: Boston Beer (NYSE:SAM) And The Rest Of The Beverages and Alcohol Segment

Business Wire

a year ago

AMTD Digital’s Half Yearly Net Profit is Estimated to Increase over 150% Year over Year

Associated Press Finance

a year ago

Lakeland Bancorp: Q4 Earnings Snapshot

Lakeland Bancorp Announces Quarterly and Year-End 2023 Earnings

GlobeNewswire

a year ago

Lakeland Bancorp Announces Quarterly and Year-End 2023 Earnings

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

GlobeNewswire

a year ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Reuters

a year ago

UPDATE 1-US FDA still reviewing Liquidia's inhaled blood pressure drug

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

GlobeNewswire

a year ago

Liquidia Corporation Provides Update on New Drug Application for YUTREPIA™ (treprostinil) inhalation powder

Newsfile

a year ago

Seabridge Gold Supports 'Close to Home' Tier 3 Neonatal Intensive Care Unit

Fiverr International (FVRR) Stock Dips While Market Gains: Key Facts

Zacks

a year ago

Fiverr International (FVRR) Stock Dips While Market Gains: Key Facts

Frontier Group Holdings Announces Webcast of Fourth Quarter 2023 Financial Results

GlobeNewswire

a year ago

Frontier Group Holdings Announces Webcast of Fourth Quarter 2023 Financial Results

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

Business Wire

a year ago

AbCellera to Report Full Year 2023 Financial Results on February 20, 2024

18 High Growth Low PE Stocks

Insider Monkey

a year ago

18 High Growth Low PE Stocks

Why Unum (UNM) Outpaced the Stock Market Today

Zacks

a year ago

Why Unum (UNM) Outpaced the Stock Market Today

3 Cheap Industrial Stocks Primed to Ride an Infrastructure Boom

InvestorPlace

a year ago

3 Cheap Industrial Stocks Primed to Ride an Infrastructure Boom

Share on Social Networks: